EntroGen Funding: How Much Did They Raise & Key Investors

How Much Did EntroGen Raise?
Funding & Key Investors

EntroGen has solidified its position within the molecular diagnostics sector, securing a total capital infusion of $706K. This latest major strategic investment of $356K underscores the firm's ongoing commitment to advancing oncology-focused diagnostic capabilities. By leveraging this financial backing, the company continues to scale its operational footprint, ensuring that its suite of diagnostic tools remains at the forefront of clinical decision-making for healthcare providers globally.

The trajectory of EntroGen reflects a sustained period of growth, characterized by consistent debt financing rounds that have enabled the company to refine its manufacturing processes and expand its portfolio of FDA-approved diagnostic solutions. This capital allocation strategy highlights a deliberate focus on long-term stability and market penetration in the highly competitive cancer diagnostics landscape.

What is EntroGen?

EntroGen

Manufacturing

Medical Devices & Equipment

Healthcare Software

EntroGen, Inc. operates as a specialized provider of molecular diagnostic solutions, primarily serving the oncology market. The company integrates automation, high-precision reagents, and proprietary software to deliver actionable insights for cancer treatment. Key products, such as the CRCdx RAS Mutation Detection and the NPM1 One-Step MRD Kit, exemplify the firm's dedication to clinical accuracy and patient-centric outcomes. Operating under strict ISO 13485 manufacturing standards, EntroGen provides essential infrastructure for healthcare organizations tasked with complex diagnostic workflows. Their market position is defined by a rigorous adherence to quality and a deep technical expertise in mutation detection, which is critical for the evolving field of precision oncology.

How much funding has EntroGen raised?

EntroGen has raised a total of $706K across 2 funding rounds:

2020

Debt

$350K

2021

Debt

$356K

Debt (2020): $350K with participation from PPP

Debt (2021): $356K led by PPP

Key Investors in EntroGen

PPP

Public-Private Partnership

What's next for EntroGen?

With the recent influx of capital, EntroGen is well-positioned to accelerate its research and development initiatives, particularly in the expansion of its diagnostic pipeline. The company is expected to prioritize the scaling of its automated diagnostic platforms, aiming to reduce turnaround times for clinical laboratories while maintaining the high sensitivity required for oncology diagnostics. Furthermore, the strategic deployment of these funds will likely support broader commercialization efforts, enabling EntroGen to penetrate new geographic markets and strengthen its partnerships with major oncology centers. As the demand for personalized medicine continues to rise, EntroGen's focus on robust, FDA-validated diagnostic tools provides a clear competitive advantage, setting the stage for sustained growth and increased influence in the molecular diagnostics ecosystem.

See full EntroGen company page

See More Financial Insights